Skip to main content
. Author manuscript; available in PMC: 2013 Apr 20.
Published in final edited form as: Sci Transl Med. 2012 Aug 22;4(148):148ra117. doi: 10.1126/scitranslmed.3003808

Fig. 4.

Fig. 4

SAH-BCL9B selectively blocks the intestinal Wnt/TCF signature. (A) qRT-PCR analysis revealed repression of Wnt target genes in response to SAH-BCL9B treatment of MM1S cells at 10 μM. Error bars are mean +/− s.d. for assays performed in quadruplicate. * p < 0.01. (A) Quantitative comparison of genes down-regulated by SAH-BCL9B and dominant-negative TCF1/TCF4 expression in DLD1 cells across adenoma (top) and carcinoma (bottom) signatures. (C) Heat map representation of the 50 most down-regulated genes (p<0.001) of the leading edge - the genes contributing most to the correlation between SAH-BCL9B and dominant-negative TCF1/TCF4 - for the adenoma (left) and carcinoma (right) signatures. (D) qRT-PCR validation of key Wnt target genes in DLD1 cells treated with SAH-BCL9B. (E) Affimetrix gene expression profiling analysis of VEGF-A in DLD1 cells.